Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human VEGFR2 Antibodies:
anti-Mouse (Murine) VEGFR2 Antibodies:
anti-Rat (Rattus) VEGFR2 Antibodies:
Go to our pre-filtered search.
Human Monoclonal VEGFR2 Primary Antibody for FACS - ABIN4896290
den Dekker, Houtgraaf, Rowland, Ligtenberg, de Boer, de Jong, de Winter, den Heijer, Zijlstra, Serruys, Cheng, Duckers: Efficiency of statin treatment on EPC recruitment depends on baseline EPC titer and does not improve angiographic outcome in coronary artery disease patients treated with the Genous stent. in Cell transplantation 2015
Show all 49 Pubmed References
Mouse (Murine) Polyclonal VEGFR2 Primary Antibody for CyTOF, FACS - ABIN4899536
Hou, Nilchi, Li, Gangaraju, Jiang, Aylsworth, Monette, Slinn: Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damage. in Scientific reports 2015
Show all 42 Pubmed References
Human Monoclonal VEGFR2 Primary Antibody for CyTOF, FACS - ABIN4899538
Riccioni, Diverio, Mariani, Buffolino, Riti, Saulle, Petrucci, Cedrone, Lo-Coco, Foà, Peschle, Testa: Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts. in Stem cells (Dayton, Ohio) 2007
Show all 10 Pubmed References
Human Polyclonal VEGFR2 Primary Antibody for IHC (p), IP - ABIN152058
Rahimi, Dayanir, Lashkari: Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. in The Journal of biological chemistry 2000
Show all 8 Pubmed References
Human Monoclonal VEGFR2 Primary Antibody for IHC (fro) - ABIN3043643
Li, Huang, Chen, Chen, Xiong, Chen, You, Jin, Liang: Oriented immobilization of anti-CD34 antibody on titanium surface for self-endothelialization induction. in Journal of biomedical materials research. Part A 2010
Show all 7 Pubmed References
Human Monoclonal VEGFR2 Primary Antibody for FACS - ABIN4896282
Wang, Tang, Sun, Miao, Lv, Yang, Zhang, Zhang, Liu, Du, Gao, Yin, Ding, Deng: TGFβ inhibition enhances the generation of hematopoietic progenitors from human ES cell-derived hemogenic endothelial cells using a stepwise strategy. in Cell research 2012
Show all 7 Pubmed References
Human Polyclonal VEGFR2 Primary Antibody for ICC, IHC (fro) - ABIN3044301
Sun, Chen, Song, Ren, Wei, Liu, Zhang, Lv: Effect of visfatin on the function of endothelial progenitor cells in high-fat-fed obese rats and investigation of its mechanism of action. in International journal of molecular medicine 2012
Show all 6 Pubmed References
Human Polyclonal VEGFR2 Primary Antibody for WB - ABIN3043274
Liu, Yang, Zhang, Shui, Song, Yao, Dai, Sun: Fructopyrano-(1?4)-glucopyranose inhibits the proliferation of liver cancer cells and angiogenesis in a VEGF/VEGFR dependent manner. in International journal of clinical and experimental medicine 2014
Show all 6 Pubmed References
Hamster Polyclonal VEGFR2 Primary Antibody for ICC, IF - ABIN250774
Gluzman-Poltorak, Cohen, Shibuya, Neufeld: Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. in The Journal of biological chemistry 2001
Show all 7 Pubmed References
Human Polyclonal VEGFR2 Primary Antibody for ELISA, ICC - ABIN6265973
Zhang, Chen, Wang, Yang, Li, Wang, Liu, Ye: Treatment of diabetes mellitus-induced erectile dysfunction using endothelial progenitor cells genetically modified with human telomerase reverse transcriptase. in Oncotarget 2018
Show all 5 Pubmed References
VEGFR-2 (KDR) polymorphism does not influence recurrent pregnancy loss susceptibility.
the findings of this study suggested that d2HG induced angiogenic activity via VEGFR2 signaling and increased MMP2 activity.
Sox7 promotes tumor growth via vessel abnormalization, and its level determines the therapeutic outcome of VEGFR2 inhibition in High-grade glioma.
R11-3 was truncated in size, and its potential in endothelial targeted therapeutics was established using VEGFR2 targeting long interfering RNA (liRNA) aptamer chimera.
ARF6 is pivotal in VEGFR2 trafficking and that targeting ARF6-mediated VEGFR2 trafficking has potential as a therapeutic approach for retinal vascular diseases such as diabetic retinopathy.
high VEGFR-1 and low VEGFR-2 expression in endothelial cells appear to be involved in the progression of colorectal cancer.
these findings indicate potential angiogenic templates and their binding levels with VEGFR-2; sorted viewpoints could be useful as a promising way to describe potential angiogenesis inhibitors with related molecular targets
Survivin in the signal downstream of VEGFR2 played an important role in esophageal cancer cell survival.
VEGFR2 was expressed by neurons, astrocytes and endothelial cells. The lack of angiogenesis despite cerebral hypoperfusion in Alzheimer's disease is not explained by altered expression of VEGFR2 or total VEGFR1.
endoglin promoted VEGF-induced tip cell formation. Mechanistically, endoglin interacted with VEGF receptor (VEGFR)-2 in a VEGF-dependent manner, which sustained VEGFR2 on the cell surface and prevented its degradation. Endoglin mutants deficient in the ability to interact with VEGFR2 failed to sustain VEGFR2 on the cell surface and to promote VEGF-induced tip cell formation.
VEGFR2 has a key role in the proangiogenic effects of rHDL in hypoxia/ischemia.
The findings indicate that miR-203a inhibits hepatocellular carcinoma cell invasion, metastasis, and angiogenesis by negatively targeting HOXD3 and suppressing cell signaling through the VEGFR pathway.
these results indicate that sFlt-1 up-regulation by VEGF may be mediated by the VEGF/Flt-1 and/or VEGF/KDR signaling pathways.
miR424 may target VEGFR2 and inhibit Hemangioma derived endothelial cell growth.
VEGFR2 is regulated by deSUMOylation during pathological angiogenesis.
This study shows that decreasing the ratio of glutathione to oxidized glutathione with diamide leads to enhanced protein S-glutathionylation, increased reactive oxygen species (ROS) production, and enhanced VEGFR2 activation.
Study confirmed prognostic effect of EGFR and VEGFR2 for recurrent disease and survival rates in patients with epithelial ovarian cancer.
none of the investigated VEGFR-2 gene polymorphisms was found to be an independent prognostic marker for infantile hemangioma.
These results suggest functional interactions among ATX, VEGFR-2, and VEGFR-3 in the modulation of hemovascular and lymphovascular cell activation during vascular development.
miR-195 suppresses cell proliferation of ovarian cancer cells through regulation of VEGFR2 and AKT signaling pathways.
These results implicate RABEP2 as a key modulator of VEGFR2 endosomal trafficking, and demonstrate the importance of RABEP2 and Rab4 for VEGFR2 signaling in endothelial cells.
Dimethyloxalylglycine protective effect on the neonatal intestinal mucosa may be mediated via VEGFR2 dependent improvement of the intestinal microvasculature
uPARAP controlVEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis.
Studied expression of vascular endothelial growth factor receptor 2 (VEGFR2) in nulliparous and parous mice.
Oleanolic acid was verified as a VEGFR-2 binding chemical from anticancer herbs with similar binding affinity as a reference drug in the Protein Data Bank (PDB) entry 3CJG of model A coordination.
significant increase in VEGFR-2 promoter activity after partial hepatectomy
Inositol 1,4,5-trisphosphate receptors (IP3Rs) are required for the hematopoietic and cardiac fate divergence of mouse embryonic stem cells. Deletion of IP3Rs (IP3R-tKO) reduced Flk1+/PDGFRalpha- hematopoietic mesoderm, c-Kit+/CD41+ hematopoietic progenitor cell population, and the colony-forming unit activity, but increased cardiac progenitor markers as well as cardiomyocytes.
Peli1 is a proangiogenic molecule that acts downstream of VEGF-Flk-1 and restores angiogenesis and enhances skin flap survivability
KDR/Flk-1 expression was revealed in mononuclear cells of the necrotic area (macrophages and fibroblast cells). The distribution of KDR/Flk-1 remained practically unchanged with lengthening of the postinfarction period (more than 7 days).
By E10.5, both Sox7 complete knockout and FLK1-specific deletion of Sox7 lead to widespread vascular defects. In contrast, while SOX7 is expressed in the earliest specified blood progenitors, the VAV-specific deletion of Sox7 does not affect the hematopoietic system. Together, our data reveal the unique role of SOX7 in vasculogenesis and angiogenesis during embryonic development.
JAM-C plays an important role in maintaining VEGR2 expression to promote retinal pigment epithelial cell survival under oxidative stress.
Genetic depletion experiments revealed that VEGFR2, but not VEGFR3, is indispensable for maintenance of thyroid vascular integrity. Notably, blockade of VEGF-A or VEGFR2 not only abrogated vascular remodeling but also inhibited follicular hypertrophy, which led to the reduction of thyroid weights during goitrogenesis.
Eriocalyxin B inhibited breast tumor angiogenesis by suppressing VEGFR-2 signaling.
transgenic mice may serve as valid models for the validation of novel therapies blocking the VEGFR-2 signaling pathway in hemangioma-like lesions and other vascular diseases
found that WT1 and KDR are co-expressed in Sertoli cells of the testes and somatic cells of embryonic ovaries. Furthermore, WT1 bound to the Kdr promoter in the chromatin of embryonic testes and ovaries. KDR signaling represses the testis-promoting gene Sox9 in embryonic XX gonads
This is the first report demonstrating the spatiotemporal expression patterns of Flk1 and Flt1 in the coronary vascular system during development and after MI; thus, this study suggests that these factors have distinct and important functions in coronary angiogenesis.
Here we demonstrate that VEGF-165 mediates MSC differentiation into ECs via VEGFR-2-dependent induction of Sox18, which ultimately coordinates the transcriptional upregulation of specific markers of the EC phenotype
NOS stimulation via PI3K, calpain proteases, and SIRT1-dependent deacetylation downstream from VEGFR2 activation contributes to these vasodilator responses.
we analyzed the expression and cellular distribution of Flt-1(VEGFR-1) and Flk-1 (KDR/VEGFR-2)in newborn piglet brain
expression of FLK1, CD146 and microvessel density of angiogenesis at the first week of reperfused acute myocardial infarction.
VEGF supplementation at the late embryonic developmental stage might improve the developmental potential of both IVF and somatic nuclear transfer preimplantation porcine embryos through its receptors.
The VEGFR2 mRNA was only upregulated in early glomerulogenesis, suggesting that VEGFR2 is important for the vascular growth.
increased placental expression of the VEGF receptor system is associated with increased placental vascular density observed with the advancement of gestation in the pig
VEGF ligand-receptor system may play an important role in the development and maintenance of the corpus luteum in pigs.
VEGF/Flk-1/Flt-1 system is activated during myocardial ischemia reperfusion injury.
Hemodialysis graft placement leads to early increases in wall shear stress, VEGF-A, pro-MMP-9, MMP-2, VEGFR-1, VEGFR-2, and TIMP-1, which may contribute to the development of venous stenosis.
binding of Neuropilin-1 to VEGFR-2 requires the PDZ-binding domain of neuropilin-1
in experimental intervertebral disc degeneration, VEGF receptors were expressed in the damaged disc and paradiscal tissues
the inhibitory effect of PEDF appears to be mediated via the processing of VEGF-R2 by gamma-secretase
VEGFR2 expression in the oviducts.
data for the first time demonstrate a calpain/PTP1B/VEGFR2 negative feedback loop in the regulation of VEGF-induced angiogenesis. Modulation of local PTP1B and/or calpain activities may prove beneficial in the treatment of impaired wound healing in diabetes.
endothelial cells exposed to TGF-beta1 lose both tip and stalk cell identity, possibly mediated by loss of VEGFR2 signaling.
These results suggest that non-dominant follicles maintain a greater concentration of the mRNA expression of both membrane and soluble VEGF receptors; but follicular dominance is related to a reduction in the mRNA expression of sVEGFR1 and sVEGFR2.
Data suggest that galectin-1 and VEGFR-2 are expressed at mid-luteal stages in luteal cells of corpus luteum; galectin-1 binds directly to asparagine-linked glycans (N-glycans) on VEGFR-2 in luteal cells.
MMP-1 promotes VEGFR2 expression and proliferation of endothelial cells through stimulation of PAR-1 and activation of NF-kappaB
The changes of sVEGFR-1 and sVEGFR-2 with the age of the bovine dominant follicle indicate a physiological role in its growth and atresia.
Vascular endothelial growth factor receptor-2 activates ADP-ribosylation factor 1 to promote endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells
VEGFR2 mRNA expression was higher at the mid and late luteal stages than at the early I and early II luteal stages, and VEGFR2 protein was higher at the mid and late luteal stages than at estrus (P<0.05)
Alterations in the expression of VEGF-A and bFGF systems suggest that angiogenic factors are involved in abnormal placental development in cloned gestations, contributing to impaired fetal development and poor survival rates.
involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS)
Placenta growth factor expression is regulated by both VEGF and hyperglycaemia via VEGFR-2.
ROS induce expression not only of VEGF but also of VEGFR2. VEGFR2 increase by ROS is mainly driven through a NF-kappaB-dependent pathway.
By regulating VEGFR2 expression and activation, PKC-epsilon expression is critical for activation of Akt and eNOS by VEGF and contributes to VEGF-stimulated Erk activation, whereas PKC-alpha has opposite effects.
These results indicate that VEGF-C-induced MSC osteogenesis is mediated through VEGFR2 and VEGFR3, and followed the activation of the ERK/RUNX2 signaling pathway.
High expression of VEGF-A/VEGFR-2 and FGF-2/FGFR-1 but not of PDGF-BB/PDGFR-beta may contribute to immature and inflammatory intraplaque angiogenesis and plaque instability in a rabbit model of atherosclerosis.
High VEGFR2 expression is associated with retinal neovascularization.
ghrelin can inhibit intraplaque angiogenesis and promote plaque stability by down-regulating VEGF and VEGFR2 expression, inhibiting the plaque content of macrophages, and reducing MCP-1 expression at an advanced stage of atherosclerosis in rabbits
Antenatal intratracheal VEGF administration was associated with an increase in Flk-1 immunoreactivity.
Intronic Flk1 genetic enhancer element directs arterial-specific expression via RBPJ-mediated venous repression.
Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas.
fetal liver kinase 1
, fetal liver kinase-1
, protein-tyrosine kinase receptor Flk-1
, soluble VEGFR2
, tyrosine kinase growth factor receptor
, vascular endothelial growth factor receptor 2
, VEGF receptor-2
, kinase NYK
, protein-tyrosine kinase receptor flk-1
, soluble vascular endothelial growth factor receptor 2
, vascular endothelial growth factor receptor- 2
, vascular endothelial growth factor receptor-2
, vascular endothelial growth factor receptor-3
, FLK1 kinase insert domain receptor (VEGF receptor 2)
, FLK1 kinase insert domain receptor (a type III receptor tyrosine kinase) (VEGF receptor 2)
, kinase insert domain protein receptor
, flk-1 receptor
, protein-tyrosine kinase
, flk-1 type VEGF receptor
, tyrosine kinase receptor
, VEGF receptor-2/Flk-1
, VEGFR-2 homolog B
, fetal liver kinase 1b
, kinase insert domain receptor (a type III receptor tyrosine kinase), b
, kinase insert domain receptor-B
, protein-tyrosine kinase receptor flk-1b
, vascular endothelial growth factor receptor 2 homolog B